Mivebresib
Mivebresib (ABBV-075) is a potent and orally active bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM[1].
Product Specifications
CAS Number
1445993-26-9
Product Name Alternative
ABBV-075
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Apoptosis; Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Mivebresib.html
Purity
99.69
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O
Molecular Formula
C22H19F2N3O4S
Molecular Weight
459.47
Precautions
H315, H319, H335
References & Citations
[1]EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15423978 1 Vial
SU-DHL-6/STAT5 Reporter (GFP-Luc) stable cell line
Sign In for Pricing
View Details 
CSB-EP661636DO1-01 10 µg
Recombinant Dog B-lymphocyte antigen CD20 (MS4A1), partial
Sign In for Pricing
View Details CSB-EP661636DO1-02 50 µg
Recombinant Dog B-lymphocyte antigen CD20 (MS4A1), partial
Sign In for Pricing
View Details CSB-EP661636DO1-03 200 µg
Recombinant Dog B-lymphocyte antigen CD20 (MS4A1), partial
Sign In for Pricing
View Details CSB-EP661636DO1-04 500 µg
Recombinant Dog B-lymphocyte antigen CD20 (MS4A1), partial
Sign In for Pricing
View Details CSB-EP661636DO1-05 20 µg
Recombinant Dog B-lymphocyte antigen CD20 (MS4A1), partial
Sign In for Pricing
View Details